Pfizer's revenue for the fourth quarter of 2025 was $17.56 billion, with a 9% growth in non-COVID business, and the full-year revenue guidance for 2026 is $59.5-62.5 billion | Financial Report Insights
Pfizer's 2025 financial report shows that the company demonstrates resilience in its strategic transformation, with a 6% growth in non-COVID core business and a steady 8% growth in oncology. Improved operational efficiency has driven profit enhancement, and the company reaffirms its revenue guidance of $59.5 billion to $62.5 billion for 2026, planning to initiate approximately 20 key clinical trials. Through acquisitions like Metsera, it is positioning itself in growth areas such as obesity, and the oncology pipeline has also made positive progress in indications such as bladder cancer and breast cancer, reflecting a continued deepening of the transition from pandemic-driven to innovation-driven
Wallstreetcn·
